John Bell (physician)
|Sir John Bell|
July 1, 1952 |
|Alma mater||University of Alberta
University of Oxford
Sir John Irving Bell, FRS, FMedSci (born 1 July 1952) is a Canadian immunologist and geneticist who resides in the UK. From 2006 to 2011, he was President of the Academy of Medical Sciences, and since 2002 has held the Regius Chair of Medicine at Oxford University, UK. He has been Chairman of OSCHR since 2006.
Education and career
Bell was born in Edmonton, Canada, where his parents worked in haematology and pharmacy. He attended Ridley College in St. Catharines, Canada. He graduated from the University of Alberta in 1975, and then studied medicine on a Rhodes Scholarship at Oxford University. In 1982, he took up a position as Clinical Fellow in Immunology with Hugh McDevitt at Stanford University, California, USA, where he worked on histocompatibility antigens and autoimmune disease.Since 2011 he has been one of two Life Sciences Champions for the UK, reporting to the Prime Minister.
In 1987 Bell returned to Oxford as a Wellcome Trust Senior Clinical Fellow, and joined the Institute of Molecular Medicine, founded by David Weatherall. In 1992 he succeeded Weatherall as the Nuffield Professor of Clinical Medicine and, in 2002, became the Regius Professor of Medicine at Oxford, also after Weatherall. In 1994, Bell was one of the founders of the Wellcome Trust Centre for Human Genetics at Oxford University. He is an emeritus fellow of Magdalen College, Oxford and a student of Christ church College. ref name=OHA_bio />He sat on the Council of the Medical Research Council 1998-2003.
Directorships, consulting and charity positions
Bell has been a non-executive director of Roche since 2001. A BMJ campaign to make the results of unpublished studies on the anti-influenza drug oseltamivir (Tamiflu) available to researchers led to the journal's editor Fiona Godlee urging Bell "as an internationally respected scientist and clinician and a leader of clinical research in the United Kingdom, to bring your influence to bear on your colleagues on Roche's board." Roche subsequently agreed to a wide policy of data transparency in clinical trials. Matthew Thompson and Carl Heneghan wrote in a letter to the journal "...according to Roche's 2011 financial report, John Bell received 390 000 Swiss Francs (£260 450; €322 450; $420 000) last year for his role on the board of directors. What do Roche and its shareholders expect for this level of involvement and remuneration?" The House of Commons Science and Technology Committee report on the subject broadly supported the release of more clinical trial data but urged caution on public release of individual patient data.
Bell serves on the Genentech Board in South Sanfrancisco, and formerly served on the scientific advisory board of AstraZeneca (1997–2000). He was the founding director of three biotechnology companies.including Oxagen, Avidex, and Powderject and is also on the Board of Atopix.
His charity positions include chairing the board of trustees of the Oxford Health Alliance and the science committee of the UK Biobank he chairs the Global Health Scientific advisory board of the Bill and Melinda Gates Foundation, he is a Trustee of the Rhodes Trust, he sits on the award jury of the Gairdner Foundation, he is a non executive member of Genomics England, he is a member of Cancer Research UK, He has advised governments and foundations in Singapore, France, Canada, Sweden, Finland, Alberta on Biomedical Research. He is on the Jenner Board, the Gray Institute Board.He is on the advisory Board for the Mc Gill Genomics Institute and the Montreal Neurological Institute and chairs the advisory board for the Oak Foudation and the Robertson Foundation.He attended the 2013 Bilderberg Group conference.
Bell's research has identified genes involved in susceptibility to diabetes mellitus type 1 and rheumatoid arthritis and multiple sclerosis His work has been important in elucidating the interactions on the surface of the T cell involved in immune activation. He has also worked on the biomedical applications of high-throughput genomic technologies, including structural genomics and ENU mutagenesis.He has been directly involved in applying genetics in a clinical settings and helped developed the 100,000 genome project in England.
Awards and honours
Bell was awarded an honorary D.Sc. by the University of Alberta in 2003. He was President of the Academy of Medical Sciences from 2006-2011. In 2008, he was elected a fellow of the Royal Society, and was knighted for services to medicine in the New Year Honours of that year.He has received honorary degrees from the Universities of York, Warwick, Glasgow, Dundee, Imperial College and University of Toronto (2014).
- "Prof Sir John Bell". Debretts. Retrieved 3 January 2013.
- Curriculum vitae: John Irving Bell (accessed 21 December 2008)
- Watts, G. (2008). "John Bell: A Canadian at the top of UK academic medicine". The Lancet 372 (9652): 1801–1822. doi:10.1016/S0140-6736(08)61748-1. PMID 19027476.
- Professor John Bell, PMedSci – A Biographical Note, 21 December 2008)
- The Oxford Health Alliance: Sir John Bell (accessed 21 December 2008)
- Roche: Board of Directors (accessed 21 December 2008)
- Godlee F. Open letter to Roche about oseltamivir trial data. BMJ 345:e7305
- Thompson M, Heneghan C. (2012) We need to move the debate on open clinical trial data forward. BMJ 345:e8351
- Roche: Finance Report 2011 (accessed 24 March 2013)
- UK Biobank: Board of Directors (accessed 21 December 2008)
- Business Insider: The Full List Of Incredibly Powerful People Who Will Attend This Year's Bilderberg Meeting (accessed 28 November 2013)
- University of Alberta: Past Honorary Degree Recipients: B (accessed 21 December 2008)
- The Academy of Medical Sciences: Governance: Honorary Officers (accessed 23 July 2012)
- Royal Society: Library and Archive catalogue: Bell; John Irving; Sir (accessed 21 December 2008)
- Royal Society: New Fellows – 2008: Agarwal–Cohen (accessed 21 December 2008)
- BBC: 29/12/07 honours list (accessed 21 December 2008)